中文 English

OncoAimTM Tumor Multi-gene Mutation and Drug Metabolism Assay

Detection method

The multiplexed targeted sequencing method used with this assay, compared to PCR and first-generation sequencing methods, is able to simultaneously detect mutations in multiple genes or regions. More genetic information can be obtained from limited amounts patient samples and quickly. 

Test significance

This assay provides guidance for targeted treatment for gene fusion related non-small cell lung cancer, including Sunitinib and Ceritinib.

Product advantage

Detection sensitivity significantly increases with the PunchAimTM technique; DNA samples as low as 2 ng may be used, which is applicable to fine needle biopsies of limited cell numbers.
Compared with conventional histology, this assay provides more accurate disease classification, diagnosis, and treatment guidance.
Simultaneous detection of somatic mutations and genotyping SNPs related to drug metabolism.
Up to 6,000 hot spot mutations and over 40 SNP sites can be detected on one sample, covering common targeted drugs for cancer and chemotherapy drugs.



Detection of genes

Tumor genes(59)

  • ABL1
  • CTNNB1
  • GNAS
  • MPL
  • RB1
  • AKT1
  • DNMT3A
  • HNF1A
  • NFE2L2
  • RET
  • ALK
  • EGFR
  • HRAS
  • NOTCH1
  • SF3B1
  • APC
  • ERBB2
  • IDH2
  • NPM1
  • SMAD4
  • ATM
  • ERBB3
  • JAK1
  • NRAS
  • SMARCB1
  • BRAF
  • ERBB4
  • JAK2
  • PAX5
  • SMO

Drug metabolism genes(14)

    • ABCB1
    • CYP2C8
    • CYP3A4
    • DPYD
    • MTHFR
    • SLC19A1
    • TPMT
    • CYP2C19
    • CYP2D6
    • CYP3A5
    • GSTP1
    • NQO1
    • SULT1A1
    • UGT1A1

Applicable to cancer patients

The test is applicable to common cancers such as lung cancer, breast cancer, colorectal cancer, esophageal cancer, and ovarian cancer when tissue samples cannot be evaluated. The product can be applied to:
Cancer patients receiving targeted therapy, in order to identify patients who will benefit most from a specific targeted drug.
Cancer patients receiving multiple treatments, in order to determine optimal treatment options and avoid toxic side effects of drugs, especially chemotherapy drugs.
Cancer patients who failed routine medical treatment, in order to find the cause of drug resistance and potential target site.  




Test procedure

*Product is for research use only.